Cochlear

Cochlear reported currency-adjusted revenue of AUD 2.3 billion (+2%) for fiscal 2026 and an adjusted net profit of AUD 322 million. Free cash flow more than doubled, operating cash flow improved by AUD 130 million, while the gross margin fell to 71%. The Nexa implant platform achieved high uptake (>95% of implant sales in developed countries) and management expects currency-adjusted revenue growth in the low single digits for 2027 and an adjusted net profit of AUD 330–350 million. The stock rose about 7.2% after the results were released. » Więcej na de.investing.com

Cochlear cut its profit forecast for the current year and cited weak consumer sentiment in the US as well as the Iran war as reasons. As a result, the shares in Sydney fell by about 41% and weighed on the market. Other market movements in the report were not specifically linked to Cochlear. » Więcej na finanzen.net

Cochlear reported first-half 2026 revenue up 1% to $1,176m, with adjusted net profit down 9% to $195m and reported net loss down 21% to $161.5m. The launch of the new Cochlear™ Nucleus® Nexa™ Systems is not expected to fully show up in the numbers in the short term; management is keeping the interim dividend at $2.15 and expects adjusted full-year earnings at the lower end of the guidance range. Investors reacted with a roughly 17% share plunge, while Cochlear aims for a stronger second half but cites currency and competitive risks. » Więcej na de.investing.com